Literature DB >> 10784307

Inhaled prostacyclin and platelet function after cardiac surgery and cardiopulmonary bypass.

A Haraldsson1, N Kieler-Jensen, H Wadenvik, S E Ricksten.   

Abstract

OBJECTIVE: To study the effects of 6 h inhalation of aerosolized prostacyclin (PGI2) on platelet function.
DESIGN: In a prospective, double-blind, randomized study, 28 patients scheduled for elective cardiac surgery requiring cardiopulmonary bypass (CPB), received either 0.9% sodium chloride (n = 8), PGI2 5 microg x ml(-1) (n = 10) or PGI2 10 microg x ml(-1) (n = 10) as an aerosol for 6 h postoperatively.
SETTING: Cardiothoracic intensive care unit at a university hospital.
INTERVENTIONS: All patients were studied immediately after surgery during mechanical ventilation and sedation. The PGI2 solutions or saline were administered with a jet nebulizer. MEASUREMENTS AND
RESULTS: Bleeding time and chest tube drainage were measured. Blood samples for platelet aggregation, thrombelastography (TEG) and analysis of coagulation parameters and the stable prostacyclin metabolite 6-keto-PGF1alpha were obtained immediately before inhalation and after 2, 4 and 6 h of inhalation. After 6 h of PGI2 inhalation, regardless of administered dose, there was a lower rate of platelet aggregation and a lower maximal increase in light transmission in response to adenosine diphosphate (ADP) than in the control group. The TEG variable reaction time (R) was prolonged after 4 and 6 h of inhalation in the PGI2 group receiving 10 microg x ml(-1). There were no differences between groups with respect to bleeding time and chest tube drainage or any of the other variables examined.
CONCLUSION: Inhalation of PGI2 for 6 h in patients after cardiac surgery is associated with impaired platelet aggregation detected by in vitro techniques, with no in vivo signs of platelet dysfunction.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10784307     DOI: 10.1007/s001340050044

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  5 in total

Review 1.  Salvage therapies for refractory hypoxemia in ARDS.

Authors:  Sujith V Cherian; Anupam Kumar; Karunakar Akasapu; Rendell W Ashton; Malaygiri Aparnath; Atul Malhotra
Journal:  Respir Med       Date:  2018-07-03       Impact factor: 3.415

Review 2.  Pharmacologic management of perioperative pulmonary hypertension.

Authors:  Julie W Cheng; Adriano R Tonelli; Gosta Pettersson; Richard A Krasuski
Journal:  J Cardiovasc Pharmacol       Date:  2014-04       Impact factor: 3.105

Review 3.  [Iloprost and selective pulmonary vasodilation. Clinical results of intraoperative and postoperative inhalation of iloprost].

Authors:  F Langer; W Wilhelm; H Lausberg; H-J Schäfers
Journal:  Anaesthesist       Date:  2004-08       Impact factor: 1.041

4.  Effect of iloprost inhalation on postoperative outcome in high-risk cardiac surgical patients: a prospective randomized-controlled multicentre trial (ILOCARD).

Authors:  Michael Winterhalter; Steffen Rex; Christian Stoppe; Peter Kienbaum; Hans-Helge Müller; Ines Kaufmann; Hermann Kuppe; Aristidis Dongas; Bernhard Zwissler
Journal:  Can J Anaesth       Date:  2019-02-12       Impact factor: 5.063

Review 5.  Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review.

Authors:  Laura C Price; Stephen J Wort; Simon J Finney; Philip S Marino; Stephen J Brett
Journal:  Crit Care       Date:  2010-09-21       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.